InsiderSignal.AI

InsiderSignal.ai

MYGN - Myriad Genetics Inc

Insider Purchase by Raha Samraat S. (Pres, CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

1 week ago, Raha Samraat S., serving as Pres, CEO at Myriad Genetics Inc (MYGN), purchased 40,000 shares at $5.00 per share, for a total transaction value of $199,844.00. Following this transaction, Raha Samraat S. now holds 493,104 shares of MYGN.

This purchase represents a 9.00% increase in Raha Samraat S.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, March 9, 2026 and publicly disclosed via SEC Form 4 filing on Monday, March 9, 2026, meaning the disclosure happened on the same day as the trade.

Myriad Genetics Inc operates in the HEALTHCARE sector, specifically within the DIAGNOSTICS & RESEARCH industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Raha Samraat S.

Raha Samraat S.

Pres, CEO

Sam Raha is the President and Chief Executive Officer of Myriad Genetics, Inc. (NASDAQ: MYGN), a position he assumed effective April 30, 2025[[2]](https://www.nasdaq.com/articles/myriad-genetics-appoints-sam-raha-ceo). He brings more than 25 years of general management, commercial, and operations experience deeply rooted in life sciences and molecular diagnostics[[3]](https://www.biospace.com/myriad-genetics-appoints-sam-raha-as-chief-operating-officer). Before his CEO appointment, Raha served as Chief Operating Officer at Myriad starting in December 2023[[1]](https://fintool.com/app/research/companies/MYGN/people/sam-s-raha), where he was responsible for driving the company's lab operations, customer service initiatives, and product development innovations[[3]](https://www.biospace.com/myriad-genetics-appoints-sam-raha-as-chief-operating-officer). Raha's career includes significant leadership roles at industry-leading diagnostics and genomics companies. He previously served as Senior Vice President and President of Agilent Technologies' Diagnostics & Genomics Group from 2018 to 2023, where he led global diagnostics and genomics businesses while managing overall strategy and financial results[[1]](https://fintool.com/app/research/companies/MYGN/people/sam-s-raha). Earlier, he held the position of Vice President of Global Marketing at Illumina from 2013 to 2017, leading global marketing for genomic platforms[[1]](https://fintool.com/app/research/companies/MYGN/people/sam-s-raha). Raha holds a Bachelor of Arts in Molecular and Cell Biology from UC Berkeley and an MBA from Santa Clara University[[1]](https://fintool.com/app/research/companies/MYGN/people/sam-s-raha). As CEO, he is focused on accelerating Myriad's growth and profitability through its comprehensive portfolio while leveraging the company's multi-year investment program and addressing patient and healthcare provider needs[[4]](https://investor.myriad.com/news-releases/news-release-detail/26051/).

View full insider profile →

Trade Price

$5.00

Quantity

40,000

Total Value

$199,844.00

Shares Owned

493,104

Trade Date

Monday, March 9, 2026

7 days ago

SEC Filing Date

Monday, March 9, 2026

HEALTHCAREDIAGNOSTICS & RESEARCH

About Myriad Genetics Inc

Company Overview

No company information available
View news mentioning MYGN

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4641251

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime